- Home
- PETS vs GNTA Comparison
PETS vs GNTA Comparison
Compare PETS & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- GNTA
- Stock Information
- Founded
- PETS 1996
- GNTA 2014
- Country
- PETS United States
- GNTA Italy
- Employees
- PETS N/A
- GNTA N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- GNTA Health Care
- Exchange
- PETS Nasdaq
- GNTA Nasdaq
- Market Cap
- PETS 118.8M
- GNTA 96.0M
- IPO Year
- PETS N/A
- GNTA 2021
- Fundamental
- Price
- PETS $5.58
- GNTA $5.12
- Analyst Decision
- PETS Sell
- GNTA Strong Buy
- Analyst Count
- PETS 2
- GNTA 1
- Target Price
- PETS $3.50
- GNTA $25.00
- AVG Volume (30 Days)
- PETS 296.2K
- GNTA 5.1K
- Earning Date
- PETS 02-06-2025
- GNTA 01-01-0001
- Dividend Yield
- PETS N/A
- GNTA N/A
- EPS Growth
- PETS N/A
- GNTA N/A
- EPS
- PETS N/A
- GNTA N/A
- Revenue
- PETS $259,343,000.00
- GNTA N/A
- Revenue This Year
- PETS N/A
- GNTA N/A
- Revenue Next Year
- PETS $3.36
- GNTA N/A
- P/E Ratio
- PETS N/A
- GNTA N/A
- Revenue Growth
- PETS N/A
- GNTA N/A
- 52 Week Low
- PETS $2.90
- GNTA $2.20
- 52 Week High
- PETS $7.79
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- PETS 56.24
- GNTA 50.15
- Support Level
- PETS $5.41
- GNTA $5.13
- Resistance Level
- PETS $6.85
- GNTA $5.27
- Average True Range (ATR)
- PETS 0.45
- GNTA 0.35
- MACD
- PETS -0.01
- GNTA 0.00
- Stochastic Oscillator
- PETS 48.37
- GNTA 40.31
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.